Sorry, you need to enable JavaScript to visit this website.
Rotate Device

Vivinex™ iSert Toric IOL

References

1. Schartmueller, D. et al. (2019): True rotational stability of a single-piece hydrophobic intraocular lens. In: The British journal of ophthalmology 103 (2), p. 186–190.

2. Brar et al. (2024): Clinical outcomes and rotational stability following implantation of a monofocal toric IOL with textured haptics in normal versus high axial lengths. In: Journal of Cataract & Refractive Surgery, 50(7):p 718-723, July 2024.

3. HOYA data on file. CTM-23-027, HOYA Medical Singapore, Pte. Ltd, 2023.

4. Auffarth, G. U et al. (2023). Randomized multicenter trial to assess posterior capsule opacification and glistenings in two hydrophobic acrylic intraocular lenses. In: Scientific reports, 13 (1), 2822.

5. Tandogan, T. et al. (2021): In-vitro glistening formation in six different foldable hydrophobic intraocular lenses. In: BMC Ophthalmol 21, 126.
6. Perez-Merino, P.; Marcos, S. (2018): Effect of intraocular lens decentration on image quality tested in a custom model eye. In: Journal of cataract and refractive surgery 44 (7), p. 889–896.

7. Chandra et al. (2022): Effect of decentration on the quality of vision: comparison between aspheric balance curve design and posterior aspheric design intraocular lenses. Journal of cataract and refractive surgery 48 (5), p. 576-583.

8. Thakur, A. et al. (2024): Effect of decentration on the quality of vision in two aspheric posterior chamber intraocular lenses: A contralateral eye study. In: Indian J Ophthalmol. 72 (4), p. 558–564.

9. Leydolt, C. et al. (2020): Posterior capsule opacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized trial. In: American journal of ophthalmology 217 (9), p. 224-231.

10. Giacinto, C. et al. (2019): Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study.In: Journal of cataract and refractive surgery 45 (9), p. 1330–1334.

11. Werner, L. et al. (2019): Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. In: Journal of cataract and refractive surgery 45 (10), p. 1490–1497.

12. Nanavaty, M. et al. (2019): Edge profile of commercially available square-edged intraocular lenses: Part 2. In: Journal of cataract and refractive surgery 45 (6), p. 847–853.

13. Matsushima, H. et al. (2006): Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 32 (6), p. 1035–1040.

14. Farukhi, A. et al. (2015): Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lens with ultraviolet-ozone treatment on the posterior surface. In: Journal of cataract and refractive surgery 41 (5), p. 1081–1087.

15. Eldred, J. et al. (2019): An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. In: Investigative ophthalmology & visual science 60 (1), p. 113–122. 

Our Vivinex™

Toric IOL

Hoya Surgical Optics iSert Toric

Proven benefits for you and your patients:

Clinically proven rotational stability. More than 96% of implanted lenses rotated ≤5° including eyes with high axial lengths1,2,3

Glistening-free hydrophobic acrylic IOL material 4,5

Incorporates the Vivinex proprietary aspheric optic design which partially compensates for corneal spherical aberration and is more tolerant to sources of coma than standard aspheric designs 6,7,8 

Active oxygen processing treatment, a smooth surface, and square optic edge to reduce PCO4,9,10,11,12,13,14,15

References

*Third-party trademarks used herein are the property of their respective owners.

1. Schartmueller, D. et al. (2019): True rotational stability of a single-piece hydrophobic intraocular lens. In: The British journal of ophthalmology 103 (2), p. 186–190.

2. Schartmueller, D. et al. (2020): Comparison of Long-Term Rotational Stability of Three Commonly Implanted Intraocular Lenses. In American journal of ophthalmology 220, pp. 72–81.

Raising the bar

Maximum rotation values observed in the first week following surgery1,2

Hoya Surgical Optics iSert Toric Hoya Surgical Optics iSert Toric

Reliable outcomes through outstanding rotational stability

The Vivinex™ IOL platform shows outstanding rotational stability between surgery and one week post op, without outliders, when compared with AcrySof®*, Tecnis®*, and enVista®*.1,2

References

*Third-party trademarks used herein are the property of their respective owners.

  1. HOYA data on file. CTM-23-027, HOYA Medical Singapore, Pte. Ltd, 2023.

Setting the standard for rotational stability

Hoya Surgical Optics iSert Toric

Distribution of absolute rotation between end of surgery and 6 months postoperative.

100% of VivinexTM Toric IOLs had less than 10° of rotation between the end of surgery and 6 months postoperatively.1

References

*Third-party trademarks used herein are the property of their respective owners.

1. Tandogan, T. et al. (2021): In-vitro glistening formation in six different foldable hydrophobic intraocular lenses. In: BMC Ophthalmol 21, 126.

2. Miyata, A. et al. (2001): Clinical and experimental observation of glistening in acrylic intraocular lenses. In: Japanese journal of ophthalmology 45 (6), p. 564–569.

3. Werner, L. et al. (2019): Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commerc ially available IOLs. In: Journal of cataract and refractive surgery 45 (10), p. 1490–1497.

Glistening-free clarity

Hoya Surgical Optics iSert IOL

In vitro glistening formation at 14x magnification1

Proven glistening-free IOL material with Grade 0 based on Miyata et al.2 in laboratory testings.1,3

References
  1. Pérez-Merino P, Marcos S. Effect of intraocular lens decentration on image quality tested in a custom model eye. J Cataract Refract Surg. 2018;44(7):889-896.

More than meets the eye

Watch how Vivinex™ improves image quality and reduces coma compared with other traditional negative aspheric IOLs.1

Play
References

1. Auffarth, G. U et al. (2023). Randomized multicenter trial to assess posterior capsule opacification and glistenings in two hydrophobic acrylic intraocular lenses. In: Scientific reports, 13 (1), 2822.

2. Leydolt, C. et al. (2020): Posterior capsule opacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized trial. In: American journal of ophthalmology 217 (9), p. 224-231.

3. Giacinto, C. et al. (2019): Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study.In: Journal of cataract and refractive surgery 45 (9), p. 1330–1334.

4. Werner, L. et al. (2019): Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. In: Journal of cataract and refractive surgery 45 (10), p. 1490–1497.

5. Nanavaty, M. et al. (2019): Edge profile of commercially available square-edged intraocular lenses: Part 2. In: Journal of cataract and refractive surgery 45 (6), p. 847–853.

6. Matsushima, H. et al. (2006): Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 32 (6), p. 1035–1040.

7. Farukhi, A. et al. (2015): Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lens with ultraviolet-ozone treatment on the posterior surface. In: Journal of cataract and refractive surgery 41 (5), p. 1081–1087.

8. Eldred, J. et al. (2019): An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. In: Investigative ophthalmology & visual science 60 (1), p. 113–122. 

What features of an IOL limit PCO?

Hoya Surgical Optics iSert IOL

Vivinex™ combines an active oxygen processing treatment, a square edge design and one of the smoothest and most  regular IOL surfaces to provide a low incidence of PCO.1,2,3,4,5,6,7,8 

 

References
  1. Matsushima, H. et al. (2006): Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 32 (6), p. 1035–1040.

Want to learn more?

Watch how our active oxygen posterior surface treatment helps to reduce PCO.1

Play
References

*Third-party trademarks used herein are the property of their respective owners.

1. Auffarth, G. U et al. (2023). Randomized multicenter trial to assess posterior capsule opacification and glistenings in two hydrophobic acrylic intraocular lenses. In: Scientific reports, 13 (1), 2822.

2. Leydolt, C. et al. (2020): Posterior capsule opacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized trial. In: American journal of ophthalmology 217 (9), p. 224-231.

Are you interested in clinical proof?

  Vivinex™ XY1 (HOYA)   AcrySof® IQ SN60WF (Alcon)
Objective
(EPCO score)
0.12 ± 0.19 n = 57 p < .026 0.24 ± 0.46 n = 57
Subjective
(slit lamp score)
0.30 ± 0.55 n = 67 p = .044 0.48 ± 0.84 n = 67
Nd:YAG rate 0.0% n = 67 p = 1.00 1.5 % n = 67
Objective
(AQUA score)
0.9 ± 0.8 n = 64 P < .001 1.4 ± 1.1 n = 62
Subjective
(slit lamp score)
1.4 ± 1.4 n = 64 P = .001 2.3 ± 2.0 n = 62
Nd:YAG rate 11.4% n = 70 p =   .23 18.6 %  n = 70

In a randomized multi-center trial, Vivinex™ demonstrated significantly lower objective and subjective PCO scores compared with AcrySof® IQ after 3 years.1

In a randomized single-center trial, Vivinex™ demonstrated significantly lower objective and subjective PCO scores compared with AcrySof® IQ after 3 years.2

These results confirm low occurrence of PCO in both IOL groups and significantly lower PCO incidence with Vivinex™ compared to AcrySof® IQ.

Vivinex™ compared to AcrySof® IQ multi-centre and single-centre trials

In a randomized multi-center trial and a randomized single-center trial, Vivinex™ demonstrated significantly lower PCO scores versus AcrySof* after 3-years. 1,2

Scroll

scroll scroll